Evidence map›Paper›PMID 41988207›Full record

ReviewFrontiers in immunology2026

Integrin β3: structural functions, tumour microenvironment regulatory roles and targeted intervention strategies.

Lianyi Peng, Fuxian Liu, Yue Yang, Liying Zhang, Shuangsheng Huang, Fei Zhao, Caili Li, Jiyu Huang, Zihan Wang, Jianxin He

Erratum issuedAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lianyi Peng *Key Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Fuxian Liu *Yunnan University of Traditional Chinese Medicine, Kunming, China.
Yue YangKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Liying ZhangKey Laboratory of Ministry of Education for Dunhuang Medicine and Transformation, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Shuangsheng HuangKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Fei ZhaoKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Caili LiKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Jiyu HuangKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Zihan WangKey Laboratory of Environmental Ecology and Population Health in Northwest Minority Areas, State Ethnic Affairs Commission, Northwest University for Nationalities, Lanzhou, Gansu, China.
Jianxin HeKey Laboratory of Ministry of Education for Dunhuang Medicine and Transformation, Gansu University of Chinese Medicine, Lanzhou, Gansu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrin β3 (ITGB3) functions as a pivotal transmembrane receptor mediating bidirectional signalling between cells and the extracellular matrix within the tumour microenvironment (TME). Dysregulated ITGB3 expression activates downstream pathways such as FAK/PI3K-Akt/mTOR, orchestrating core malignant processes including invasion, metastasis, angiogenesis, immune evasion, and autophagy modulation. Beyond its mechanistic roles, ITGB3 serves as a valuable biomarker for early diagnosis and prognostic assessment. Therapeutic strategies targeting ITGB3 encompass small-molecule inhibitors, monoclonal antibodies, and emerging Traditional Chinese Medicine (TCM) formulations, which offer unique multi-component regulatory advantages. This review systematically elucidates the structure-function relationship of ITGB3, its multidimensional regulatory mechanisms in tumour progression, and current targeted intervention strategies. Ultimately, we aim to provide theoretical insights for establishing ITGB3-guided precision medicine and integrated treatment systems.

Indexed as

Integrin beta3NeoplasmsTumor MicroenvironmentAnimalsGene Expression Regulation, NeoplasticHumansMolecular Targeted TherapyNeovascularization, PathologicSignal TransductionIntegrin beta3ITGB3 protein, humanangiogenesisintegrin β3 (ITGB3)targeted therapytraditional Chinese medicinetumour microenvironment

Identifiers

PMID41988207
PMCPMC13077601

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.